Compare EXG & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXG | HAE |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2006 | 1996 |
| Metric | EXG | HAE |
|---|---|---|
| Price | $8.64 | $58.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $85.38 |
| AVG Volume (30 Days) | 518.3K | ★ 619.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.54 |
| EPS | N/A | ★ 2.46 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.31 |
| P/E Ratio | ★ N/A | $23.79 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.74 | $47.32 |
| 52 Week High | $9.78 | $87.32 |
| Indicator | EXG | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 21.76 | 34.23 |
| Support Level | $8.49 | $48.47 |
| Resistance Level | $8.89 | $66.86 |
| Average True Range (ATR) | 0.13 | 1.53 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 11.35 | 10.70 |
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.